This study investigated mutations in the untranslated regions (UTRs) of EGFR, AKT1, and HRAS genes in Pakistani colorectal cancer patients. Whole-exome sequencing and extensive in silico analysis identified several UTR mutations. These alterations demonstrated significant functional impacts, including the loss or gain of transcription factor binding sites, changes in mRNA stability, and the loss of oncomiR binding sites. The findings suggest that these UTR mutations could dysregulate the expression of these oncogenes and contribute to colorectal cancer progression.
A study involving 5420 non-small cell lung cancer (NSCLC) cases investigated the prevalence and impact of coexisting driver genetic alterations. Coexisting mutations were found in 3.9% of tumors, more frequently in females, with KRAS and PIK3CA being the most common combination. Clonality analysis revealed KRAS and EGFR as initiating drivers, while PIK3CA, AKT1, and IDH1 were mostly secondary events. The presence of EGFR + KRAS mutations was significantly associated with worse overall survival in both early and advanced stages. These findings emphasize the importance of comprehensive genomic profiling for effective therapeutic management.
This review examines established and emerging biomarkers for stratifying patients with early-stage breast cancer to optimize adjuvant systemic therapy. It highlights that while clinicopathological factors remain fundamental, decision-making is increasingly driven by precise biological markers. ER and HER2 status are crucial, and multigene assays refine recurrence risk and chemotherapy benefit in hormone receptor-positive cancers. Immune and DNA-repair biomarkers inform targeted therapies in HER2-positive and triple-negative subtypes, while mutation profiling of genes like ESR1, PIK3CA, AKT, MTOR, and PTEN guides targeted treatments. Emerging approaches, including liquid biopsy and artificial intelligence, offer dynamic insights but require prospective validation.